SCHEMBL10035971

SCHEMBL10035971

O=C1/C(=C\c2sc(=S)n(-c3ccccc3)c2O)SC(=S)N1c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
ALDH1A1 P00352 4/20 0.54
THRB P10828 2/20 0.54
MAPT P10636 7/20 0.53
KDM4E B2RXH2 2/20 0.53
POLB P06746 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPK1 P28482 2/20 0.53
DUSP22 Q9NRW4 8/20 0.52
DUSP3 P51452 2/20 0.49
MCL1 Q07820 1/20 0.49
AMY1A P0DUB6 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
SAE1 Q9UBE0 1/20 0.47
UBA2 Q9UBT2 1/20 0.47
GFER P55789 1/20 0.47
TDP1 Q9NUW8 2/20 0.47
RECQL P46063 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14065931 0.76 MAPT (0.66) MEN1KMT2AALDH1A1THRBMAPT
SCHEMBL12123516 0.76 DUSP22 (0.77) MEN1KMT2AALDH1A1THRBMAPT
SCHEMBL9917038 0.76 DUSP22 (0.77) MEN1KMT2AALDH1A1THRBMAPT
SCHEMBL10035996 0.76 DUSP22 (0.77) MEN1KMT2AALDH1A1THRBMAPT
SCHEMBL10035969 0.76 MEN1 (0.73) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL2403957 0.72 HSPD1 (0.81) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL2403963 0.72 HSPD1 (0.81) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL2403960 0.72 HSPD1 (0.81) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL11116026 0.72 MAPT (0.60) MEN1KMT2AALDH1A1THRBMAPT
SCHEMBL6720202 0.72 MEN1 (0.65) MEN1KMT2AALDH1A1THRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MEN1 2218/4885KMT2A 2624/4885ALDH1A1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.